Emerging treatment modalities for advanced pancreatic neuroendocrine tumors

Hormones (Athens). 2016 Oct;15(4):563-564. doi: 10.14310/horm.2002.1702.

Authors

Alessandro Sindoni¹, Fausto Famà², Maria Gioffre-Florio², Sergio Baldari³

Affiliations

¹ Department of Biomedical and Dental Sciences and of Morphological and Functional Images, University Hospital of Messina, 1 Via Consolare Valeria, 98125, Messina, Italy. alessandrosindoni@alice.it.
² Department of Human Pathology, University Hospital of Messina, Messina, Italy.
³ Department of Biomedical and Dental Sciences and of Morphological and Functional Images, University Hospital of Messina, 1 Via Consolare Valeria, 98125, Messina, Italy.

PMID: 28222417
DOI: 10.14310/horm.2002.1702

No abstract available

Publication types

Letter

MeSH terms

Humans
Neuroendocrine Tumors / therapy*
Octreotide / analogs & derivatives*
Octreotide / therapeutic use
Organometallic Compounds / therapeutic use*
Pancreatic Neoplasms / therapy*
Radiopharmaceuticals / therapeutic use*
Receptors, Peptide*

Substances

Organometallic Compounds
Radiopharmaceuticals
Receptors, Peptide
lutetium Lu 177 dotatate
Octreotide